[go: up one dir, main page]

ATA144090A - Formulierungen mit verlangsamter freisetzung wasserlöslicher peptide - Google Patents

Formulierungen mit verlangsamter freisetzung wasserlöslicher peptide

Info

Publication number
ATA144090A
ATA144090A AT0144090A AT144090A ATA144090A AT A144090 A ATA144090 A AT A144090A AT 0144090 A AT0144090 A AT 0144090A AT 144090 A AT144090 A AT 144090A AT A144090 A ATA144090 A AT A144090A
Authority
AT
Austria
Prior art keywords
formulations
water
slow release
soluble peptides
peptides
Prior art date
Application number
AT0144090A
Other languages
English (en)
Other versions
AT406225B (de
Original Assignee
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh
Publication of ATA144090A publication Critical patent/ATA144090A/de
Application granted granted Critical
Publication of AT406225B publication Critical patent/AT406225B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT0144090A 1989-07-07 1990-07-06 Formulierungen mit verlangsamter freisetzung wasserlöslicher peptide AT406225B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37702389A 1989-07-07 1989-07-07
US41134789A 1989-09-22 1989-09-22

Publications (2)

Publication Number Publication Date
ATA144090A true ATA144090A (de) 1999-08-15
AT406225B AT406225B (de) 2000-03-27

Family

ID=27007654

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0144090A AT406225B (de) 1989-07-07 1990-07-06 Formulierungen mit verlangsamter freisetzung wasserlöslicher peptide

Country Status (27)

Country Link
JP (5) JPH0832624B2 (de)
KR (2) KR100303681B1 (de)
AT (1) AT406225B (de)
AU (2) AU641407B2 (de)
BE (1) BE1004486A3 (de)
CA (1) CA2020477C (de)
CH (1) CH685230A5 (de)
CY (1) CY1965A (de)
DE (2) DE4021517B4 (de)
DK (1) DK175849B1 (de)
FI (3) FI108611B (de)
FR (1) FR2649319A1 (de)
GB (2) GB2234896B (de)
GR (1) GR1001121B (de)
HK (2) HK97695A (de)
HU (2) HU221294B1 (de)
IE (2) IE64411B1 (de)
IL (3) IL131880A (de)
IT (1) IT1241460B (de)
LU (1) LU87764A1 (de)
MY (1) MY106722A (de)
NL (1) NL195027C (de)
NO (2) NO302928B1 (de)
NZ (1) NZ234384A (de)
PT (1) PT94628B (de)
SE (1) SE512992C2 (de)
SG (1) SG26416G (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
DE4218510A1 (de) * 1992-06-02 1993-12-09 Pharmatech Gmbh Verfahren zur Herstellung biologisch abbaubarer Polyester
AU4198793A (en) † 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
EP0626170A3 (de) * 1993-05-10 1996-03-27 Sandoz Ltd Stabilisierung pharmakologisch aktiver Verbindungen in Mitteln mit verzögerter Freisetzung.
GB9310781D0 (en) * 1993-05-25 1993-07-14 Davis Stanley S Preparation of microparticles
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
DK0729357T3 (da) 1993-11-19 2005-06-06 Janssen Pharmaceutica Nv Mikroindkapslede 1,2-benzazoler
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
EP0965336A1 (de) 1995-11-09 1999-12-22 Microbiological Research Authority Mikroverkapselte DNA zur Gentherapie
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US7107268B1 (en) 1998-11-12 2006-09-12 Printable Technologies, Inc. Centralized system and method for managing enterprise operations
US6226656B1 (en) 1998-11-12 2001-05-01 Sourcefinder, Inc. System and method for creating, generating and processing user-defined generic specs
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
EP1044683A1 (de) 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. Einschrittdispersionsverfahren zur Mikroverkapselung von wasserlöslichen Substanzen
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
AU2002232824A1 (en) 2000-12-21 2002-07-01 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
PE20050285A1 (es) * 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
ES2600554T3 (es) * 2003-07-18 2017-02-09 Oakwood Laboratories L.L.C. Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
KR20060129394A (ko) * 2004-02-26 2006-12-15 독립행정법인 과학기술진흥기구 단백성 약물의 주사용 서방성 미립자 제제 및 이의제조방법
DE102004053373A1 (de) * 2004-11-02 2006-05-04 Justus-Liebig-Universität Giessen Erfindung betreffend anisometrische Partikel in Form von Nano-/Meso-Fasern -Röhren, -Kabeln -Bändern und deren gekrümmte oder verzweigte Abwandlungen
KR100741867B1 (ko) * 2005-07-05 2007-07-24 전북대학교산학협력단 수중유적 및 용매 증발법을 이용한 이중층 미립구의제조방법
AR058591A1 (es) * 2005-12-22 2008-02-13 Novartis Ag Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-coglicolido
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
AU2009209594A1 (en) 2008-01-30 2009-08-06 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP2621474A2 (de) * 2010-09-30 2013-08-07 Evonik Corporation Emulsionsverfahren zur herstellung von mikropartikeln mit niedrigem restlösemittelgehalt
JP5808413B2 (ja) * 2010-09-30 2015-11-10 エボニック コーポレイションＥｖｏｎｉｋ Ｃｏｒｐｏｒａｔｉｏｎ 微粒子から残留有機溶剤を除去する方法
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
KR102464650B1 (ko) 2016-05-03 2022-11-10 엘에스일렉트릭(주) 배선용 차단기의 한류장치
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH644768A5 (de) * 1977-08-25 1984-08-31 Sandoz Ag Verfahren zur herstellung von mikrokugeln.
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
EP0029579B1 (de) * 1979-11-27 1983-02-16 Sandoz Ag Polypeptide, Verfahren zu ihrer Herstellung, pharmazeutische Zusammensetzungen, die diese Polypeptide enthalten, und ihre Verwendung
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US4485101A (en) * 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
JPH0657658B2 (ja) * 1985-04-11 1994-08-03 住友製薬株式会社 徐放性製剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8331158D0 (en) * 1983-11-22 1983-12-29 British Telecomm Metal/semiconductor deposition
JPS60181029A (ja) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
CH660302A5 (fr) * 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
EP0190833B1 (de) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung von Mikrokapseln
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
CH665558A5 (en) * 1985-10-09 1988-05-31 Debiopharm Sa Phase sepn. prodn. of microcapsules for water soluble pharmaceuticals - using fluoro-substd. aliphatic hydrocarbon as non-solvent in the hardening stage
JP2539789B2 (ja) * 1986-03-06 1996-10-02 日本原子力研究所 ポリラクトンからなる徐放性薬物複合体の製造方法
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH672887A5 (de) * 1987-10-14 1990-01-15 Debiopharm Sa
DE3738228A1 (de) * 1987-11-11 1989-05-24 Hoechst Ag Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル

Also Published As

Publication number Publication date
HUT54037A (en) 1991-01-28
JP2931773B2 (ja) 1999-08-09
JPH08198771A (ja) 1996-08-06
FI903429A0 (fi) 1990-07-06
PT94628A (pt) 1991-03-20
PT94628B (pt) 1997-06-30
CA2020477C (en) 2000-11-21
HU221294B1 (en) 2002-09-28
GB2265311B (en) 1994-02-09
KR910002430A (ko) 1991-02-25
SE9002364L (sv) 1991-01-08
IT9048113A0 (it) 1990-07-05
GB9306204D0 (en) 1993-05-19
DK162590A (da) 1991-01-08
FI109334B (fi) 2002-07-15
IL94983A (en) 1999-08-17
CY1965A (en) 1997-07-04
IT9048113A1 (it) 1992-01-05
GR1001121B (el) 1993-04-28
DE4042752B4 (de) 2009-05-07
NZ234384A (en) 1994-05-26
IT1241460B (it) 1994-01-17
CH685230A5 (de) 1995-05-15
DE4021517B4 (de) 2009-04-09
FR2649319B1 (de) 1994-12-09
NO320444B1 (no) 2005-12-05
LU87764A1 (fr) 1992-03-11
FI109543B (fi) 2002-08-30
GB9014704D0 (en) 1990-08-22
IL131880A (en) 2001-12-23
GB2234896B (en) 1994-01-19
SE9002364D0 (sv) 1990-07-05
AU5874690A (en) 1991-01-10
HK97695A (en) 1995-06-23
IE902435A1 (en) 1991-02-13
IE64216B1 (en) 1995-07-26
IL94983A0 (en) 1991-06-10
IL131881A (en) 2001-12-23
IE64411B1 (en) 1995-08-09
HU903974D0 (en) 1990-11-28
NO903001L (no) 1991-01-08
KR100303681B1 (ko) 2002-05-16
NL195027C (nl) 2003-12-02
DK162590D0 (da) 1990-07-05
GB2234896A (en) 1991-02-20
AU641407B2 (en) 1993-09-23
AU2332195A (en) 1995-09-07
FI20000059A (fi) 2000-01-12
BE1004486A3 (fr) 1992-12-01
CA2020477A1 (en) 1991-01-08
HK197496A (en) 1996-11-08
JP2001233897A (ja) 2001-08-28
FR2649319A1 (fr) 1991-01-11
JPH07285853A (ja) 1995-10-31
JPH0368511A (ja) 1991-03-25
NL9001537A (nl) 1991-02-01
DK175849B1 (da) 2005-03-29
JPH07309897A (ja) 1995-11-28
NO302928B1 (no) 1998-05-11
GR900100513A (en) 1991-12-10
AT406225B (de) 2000-03-27
DE4021517A1 (de) 1991-01-17
SE512992C2 (sv) 2000-06-12
FI108611B (fi) 2002-02-28
NO983923L (no) 1991-01-08
NL195027B (nl) 2003-08-01
HU211602A9 (en) 1995-12-28
GB2265311A (en) 1993-09-29
SG26416G (en) 1995-09-01
KR100442931B1 (ko) 2004-08-02
MY106722A (en) 1995-07-31
JPH0832624B2 (ja) 1996-03-29
FI20000060A (fi) 2000-01-12
NO983923D0 (no) 1998-08-26
AU687553B2 (en) 1998-02-26
NO903001D0 (no) 1990-07-05

Similar Documents

Publication Publication Date Title
ATA144090A (de) Formulierungen mit verlangsamter freisetzung wasserlöslicher peptide
DK518988D0 (da) Vanduoploeseligt polypeptidpraeparat
PH30995A (en) Sustained release formulations of water soluble peptides.
NO922005D0 (no) Farmasoeytiske preparater
BR9006934A (pt) Formulacoes aquosas estabilizadas de pequenos peptidios
DK163689D0 (da) Peptidderivater
DK0403917T3 (da) Højkoncentrerede faste pigmentpræparater
DK210590D0 (da) Hirudinpeptider
DK499886A (da) Peptid
DK197989A (da) Peptidanaloger
KR920700222A (ko) 동결건조된 펩티드 제제
DK177789D0 (da) Peptidderivater
NO177858C (no) Peptid
IT9020593A0 (it) procedimento per la preparazione
NO891926D0 (no) Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater.
FI991120A0 (fi) Vesiliukoisten peptidien pitkäaikaisesti vapautuvat koostumukset
DK149591A (da) Proteinpraeparat
DK258788D0 (da) Peptidpraeparat
DK136088D0 (da) Peptid
ZA905327B (en) Sustained release formulations of water soluble peptides
CY1844A (en) Sustained release formulations of water soluble peptides
DK171489D0 (da) Peptidderivater
CS8904973A1 (en) Peptides with accumulated pair of basic amino acids
IT8907005A0 (it) Riposizionatore dentale rapido
IE893135L (en) Hiv proteins and peptides

Legal Events

Date Code Title Description
ELA Expired due to lapse of time